Related Experiment Videos

Effect of proton pump inhibitor therapy on inflammatory changes in the gastric cardia (carditis)

Shailender Singh1, Ajay Bansal, Srinivas Puli

  • 1University of Kansas School of Medicine and Veterans Affairs Medical Center, Kansas City, Kansas, Missouri 64128, USA.

Insights

Proton pump inhibitor (PPI) therapy did not significantly reduce inflammation in the gastric cardia. These findings suggest gastroesophageal reflux disease (GERD) may not be a primary cause of carditis.

Area of Science:

  • Gastroenterology
  • Pathology

Background:

  • The causes of gastric cardia inflammation (carditis) are debated.
  • Gastroesophageal reflux disease (GERD) and H. pylori infection are potential etiological factors.

Purpose of the Study:

  • To assess the impact of acid suppression on histological changes in the gastric cardia.
  • To evaluate the efficacy of proton pump inhibitors (PPIs) in managing carditis.

Main Methods:

  • Gastric cardia biopsies from reflux patients were analyzed before and after PPI therapy.
  • The updated Sydney classification was used to score histological findings.
  • Carditis, intestinal metaplasia, and atrophy scores were compared pre- and post-treatment.

Main Results:

  • No significant reduction in carditis scores was observed after prolonged PPI therapy (mean 30 months).
  • Mean mononuclear and neutrophil scores showed a slight, non-significant increase post-PPI therapy.
  • Intestinal metaplasia and atrophy scores remained unchanged.

Conclusions:

  • Acid suppressive therapy with PPIs did not significantly decrease carditis scores.
  • GERD is unlikely to be a major factor in the pathogenesis of gastric cardia inflammation.

Related Concept Videos

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
Gastritis II: Pathophysiology01:26

Gastritis II: Pathophysiology

The pathophysiology of gastritis begins with the colonization of the stomach lining by Helicobacter pylori (H. pylori). This bacterium spreads mainly via the oral-oral route through saliva or shared utensils, and can also be transmitted in overcrowded or unhygienic environments through contaminated water, despite its brief survival outside the body.ColonizationOnce ingested, H. pylori enters the stomach and begins colonization by navigating through the mucus layer lining the stomach wall. It...
Pathophysiology of Peptic Ulcer Disease: Injurious Factors01:22

Pathophysiology of Peptic Ulcer Disease: Injurious Factors

Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds to M3...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...